Skip to main content
. 2019 Jul 9;10:199–208. doi: 10.2147/JBM.S202286

Figure 2.

Figure 2

(A) Overall survival with ibrutinib versus FCR and chlorambucil monotherapy, (B) progression-free survival with ibrutinib versus FCR and chlorambucil monotherapy. FCR, fludarabine, cyclophosphamide, rituximab.